Trial reportArchives of gynecology and obstetrics2019
A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Trial report in Archives of gynecology and obstetrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Effect of oral contraceptive use on cardiorespiratory and immune function in premenopausal women involved in exercise: a systematic review and meta-analysis.Frontiers in physiology · 2026Pooled it
- Efficacy and safety of drospirenone as a progestin-only pill in Japanese women: A phase III study.The journal of obstetrics and gynaecology research · 2025Trial
- Drospirenone 4 mg in a 24 + 4 regimen in women with contraindications to oestrogen use for contraception: bleeding patterns according to previous menstrual characteristics.Archives of gynecology and obstetrics · 2023Trial
- Combined Oral Contraceptive Pills Versus Progestin-Only Pills for Heavy Menstrual Bleeding: A Systematic Review.Cureus · 2026Review
- Use of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome.Archives of gynecology and obstetrics · 2025Observational
- The progestin revolution 2: progestins are now a dominant player in the tight interlink between contraceptive protection and bleeding control-plus more.Contraception and reproductive medicine · 2023Article
- The efficacy, acceptability and continuation of postpartum, post-abortive progestin-only pill: a pioneering prospective multicentric study from TurkeyJournal of the Turkish German Gynecological Association · 2022Article
- Progestogen-only oral contraceptives.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.Geburtshilfe und Frauenheilkunde · 2021Article
- The Progestin Revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control.Contraception and reproductive medicine · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA typical compliance problem in the use of traditional progestin-only pills is the irregular bleeding pattern and the strict daily intake. Desogestrel 75 mg has a 12-h missed-pill window; however, its poor cycle control limits a more common use.
methodsA drospirenone (DRSP)-only pill was developed to improve the bleeding profile.
settingA phase III study in healthy women aged 18-45 years was performed to compare the bleeding profile and safety of a DRSP-only pill in a regime of 24 days of 4 mg of DRSP tablets followed by 4 days of placebo versus desogestrel 0.075 mg per day continuously over nine cycles. POPULATION: A total of 858 women with 6691 drospirenone and 332 women with 2487 desogestrel treatment cycles were analyzed.
main outcome measuresThe primary end point was the proportion of women with unscheduled bleeding/spotting in each cycle from cycles 2 to 9 and cumulative in cycles 2-4 and cycles 7-9.
resultsIn each cycle, up to cycle 7, the proportion of women with unscheduled bleeding was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, Chi-square test).
conclusionsThis report describes the improvement in bleeding profile of women using the new DRSP-only oral contraceptive in comparison to DSG, providing a better quality of live and adherence to the contraceptive method. EudraCT Registration Number: 2011-002396-42.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.